Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03955939 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT03955939 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 5 participants.
The verdict
NCT03955939, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The reason for this study is to determine the recommended phase 2 dose of the study drug LY3295668 erbumine in participants with breast cancer that has spread to other parts of the body.
Interventions
- DRUG Midazolam
- DRUG Endocrine therapy
- DRUG LY3295668 Erbumine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-08-02 |
| Est. Completion | 2020-05-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03955939
The ClinicalTrials.gov registry entry for NCT03955939 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Midazolam is the first listed.
NCT03955939 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03955939 about?
NCT03955939 is a clinical study titled "A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body". The reason for this study is to determine the recommended phase 2 dose of the study drug LY3295668 erbumine in participants with breast cancer that has spread to other parts of the body.
What is the current status of trial NCT03955939?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2019-08-02. Estimated completion is 2020-05-14.
What interventions are being tested in trial NCT03955939?
The interventions under investigation include: Midazolam (DRUG), Endocrine therapy (DRUG), LY3295668 Erbumine (DRUG).
Who is sponsoring clinical trial NCT03955939?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.